New study tests alternative to prevent bone loss after stopping popular osteoporosis drug

NCT ID NCT07406685

Summary

This study aims to find out if a drug called ibandronate works as well as the current standard drug, zoledronic acid, to protect bones after women stop taking denosumab for osteoporosis. It will involve 52 postmenopausal women who have taken denosumab for less than three years. Researchers will measure changes in bone density and strength over two years to see which treatment better prevents bone loss and fractures.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.